Loading clinical trials...
Loading clinical trials...
An Open-label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults With Parkinson's Disease and Depression
Conditions
Interventions
Pimavanserin
Locations
21
United States
ATP Clinical Research, Inc.
Costa Mesa, California, United States
The Parkinson's and Movement Disorder Institute
Fountain Valley, California, United States
SC3 Research-Reseda
Pasadena, California, United States
The Neurology Group
Pomona, California, United States
SC3 Research-Reseda
Reseda, California, United States
CNS Network
Torrance, California, United States
Start Date
March 9, 2018
Primary Completion Date
July 9, 2019
Completion Date
July 24, 2019
Last Updated
August 31, 2020
Lead Sponsor
ACADIA Pharmaceuticals Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions